Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Defined term · Regulatory

Notoriety bias

Increased reporting of an adverse event following publicity about it, which inflates a pharmacovigilance signal without any change in incidence.

Document identifier
CEI-GT-180
Series
Defined term
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Notoriety bias

§1.2Category

Regulatory — Terms describing the status of a compound before a competent authority.

§1.3Related terms

  • Pharmacovigilance — The collection and analysis of reports of suspected adverse reactions after authorisation. Establishes that an event has been reported and, for an event named in a…
Compound Evidence Institute · CEI-GT-180 · https://compoundevidence.com/glossary/notoriety-bias/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.